PL2799431T3 - Nowa pochodna nikotynamidu lub jej sól - Google Patents

Nowa pochodna nikotynamidu lub jej sól

Info

Publication number
PL2799431T3
PL2799431T3 PL11878563T PL11878563T PL2799431T3 PL 2799431 T3 PL2799431 T3 PL 2799431T3 PL 11878563 T PL11878563 T PL 11878563T PL 11878563 T PL11878563 T PL 11878563T PL 2799431 T3 PL2799431 T3 PL 2799431T3
Authority
PL
Poland
Prior art keywords
salt
nicotinamide derivative
novel nicotinamide
novel
derivative
Prior art date
Application number
PL11878563T
Other languages
English (en)
Inventor
Hideyasu Fujiwara
Shinsuke Mizumoto
Yohei Kubo
Hiyoku Nakata
Shinji Hagiwara
Yasutaka Baba
Takashi Tamura
Hidenobu Kuniyoshi
Tomoyuki Mashiko
Mari Yamamoto
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of PL2799431T3 publication Critical patent/PL2799431T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
PL11878563T 2011-12-28 2011-12-28 Nowa pochodna nikotynamidu lub jej sól PL2799431T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011288205A JP5868168B2 (ja) 2011-12-28 2011-12-28 新規なニコチンアミド誘導体またはその塩
PCT/JP2011/080597 WO2013099041A1 (ja) 2011-12-28 2011-12-28 新規なニコチンアミド誘導体またはその塩
EP11878563.3A EP2799431B1 (en) 2011-12-28 2011-12-28 Novel nicotinamide derivative or salt thereof

Publications (1)

Publication Number Publication Date
PL2799431T3 true PL2799431T3 (pl) 2018-07-31

Family

ID=48696599

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11878563T PL2799431T3 (pl) 2011-12-28 2011-12-28 Nowa pochodna nikotynamidu lub jej sól

Country Status (22)

Country Link
US (1) US9051310B2 (pl)
EP (1) EP2799431B1 (pl)
JP (1) JP5868168B2 (pl)
KR (1) KR101744607B1 (pl)
CN (1) CN104024226B (pl)
AU (1) AU2016202949A1 (pl)
BR (1) BR112014016328A8 (pl)
CA (1) CA2861202C (pl)
DK (1) DK2799431T3 (pl)
ES (1) ES2661444T3 (pl)
IL (1) IL233385B (pl)
MX (1) MX362940B (pl)
MY (1) MY188000A (pl)
NO (1) NO2799431T3 (pl)
NZ (1) NZ627250A (pl)
PH (1) PH12014501486B1 (pl)
PL (1) PL2799431T3 (pl)
RU (1) RU2576623C2 (pl)
SG (1) SG11201403744YA (pl)
TW (1) TWI546287B (pl)
WO (1) WO2013099041A1 (pl)
ZA (1) ZA201405503B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635556B1 (en) * 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
BR112017021408B1 (pt) 2015-04-08 2022-05-17 Bayer Cropscience Aktiengesellschaft Derivados de heterociclo bicíclico condensado, método para controlar pragas animais, e formulação agroquímica
RU2018108149A (ru) 2015-08-07 2019-09-09 Байер Кропсайенс Акциенгезельшафт 2-(гет)арил-замещенные конденсированные гетероциклические производные в качестве средства для борьбы с вредителями
JP6472419B2 (ja) 2015-09-30 2019-02-20 富士フイルム株式会社 芳香族化合物の製造方法
MX2018005115A (es) 2015-10-26 2018-05-28 Bayer Cropscience Ag Derivados de heterociclos biciclicos condensados como agentes de control de plagas.
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017174414A1 (de) 2016-04-05 2017-10-12 Bayer Cropscience Aktiengesellschaft Naphthalin-derivate als schädlingsbekämpfungsmittel
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
US10561145B2 (en) 2016-07-19 2020-02-18 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
AU2017314083B2 (en) 2016-08-15 2020-12-10 Bayer Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
AU2017328614B2 (en) 2016-09-19 2022-01-13 Bayer Aktiengesellschaft Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
CN107056695A (zh) * 2017-01-26 2017-08-18 青岛辰达生物科技有限公司 一种治疗胃癌药物阿帕替尼的合成方法
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN108689936B (zh) * 2017-04-10 2021-09-10 西华大学 含氮取代基的吲唑类化合物及其作为ido抑制剂的用途
EP3305786A3 (de) 2018-01-22 2018-07-25 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
JP2021514949A (ja) 2018-02-21 2021-06-17 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としての縮合二環式ヘテロ環誘導体
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
US20220204499A1 (en) 2019-02-26 2022-06-30 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
CN113710669A (zh) 2019-02-26 2021-11-26 拜耳公司 作为农药的稠合双环杂环衍生物
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
CN114230490A (zh) * 2021-12-28 2022-03-25 乐威医药(江苏)股份有限公司 一种n-烷基化双胺的制备方法
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
CN114349691A (zh) * 2022-01-25 2022-04-15 阿里生物新材料(常州)有限公司 一种3,4-二氟-2-甲氧基-吡啶的合成方法
CN116535324A (zh) * 2023-07-07 2023-08-04 广东嘉博制药有限公司 一种苏式构型盐酸甲氧明的制备方法
CN117285459B (zh) * 2023-11-24 2024-02-27 上海美迪西生物医药股份有限公司 一种小分子激酶抑制剂化合物的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133253A (en) 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
IL144834A0 (en) 1999-02-16 2002-06-30 Basf Ag Process for the preparation of 6-(perfluoroalkyl) uracil compounds from carbamate compounds
ATE288420T1 (de) 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
EP1306372B1 (en) 2000-03-31 2009-11-18 Nippon Shinyaku Co., Ltd. Heterocycle derivatives and drugs
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20060079522A1 (en) 2004-10-08 2006-04-13 Marzabadi Mohammad R Amino substituted aryloxybenzylpiperidine derivatives
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
KR101411695B1 (ko) 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd 5−シアノニコチンアミド誘導体
US20080020094A1 (en) 2006-07-19 2008-01-24 Lager Bernard G Activated cranberry powder
EP1932845A1 (en) 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
AR068509A1 (es) 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
CA2960692C (en) 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
US8658159B2 (en) 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 4,6−ジアミノニコチンアミド化合物
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2589592B1 (en) * 2010-06-30 2018-08-22 FUJIFILM Corporation Novel nicotinamide derivatives or salts thereof
EP2635556B1 (en) * 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators

Also Published As

Publication number Publication date
ES2661444T3 (es) 2018-04-02
US20140309225A1 (en) 2014-10-16
MY188000A (en) 2021-11-08
KR20140104504A (ko) 2014-08-28
AU2011384478B2 (en) 2016-05-26
MX2014007785A (es) 2014-07-30
CN104024226B (zh) 2016-06-01
PH12014501486A1 (en) 2014-09-22
PH12014501486B1 (en) 2014-09-22
IL233385A0 (en) 2014-08-31
NZ627250A (en) 2016-04-29
KR101744607B1 (ko) 2017-06-08
EP2799431B1 (en) 2018-01-24
EP2799431A4 (en) 2015-05-13
SG11201403744YA (en) 2014-09-26
TW201326127A (zh) 2013-07-01
CA2861202C (en) 2018-03-13
AU2016202949A1 (en) 2016-05-26
US9051310B2 (en) 2015-06-09
JP2013136535A (ja) 2013-07-11
BR112014016328A2 (pt) 2017-06-13
JP5868168B2 (ja) 2016-02-24
DK2799431T3 (en) 2018-03-26
WO2013099041A1 (ja) 2013-07-04
RU2576623C2 (ru) 2016-03-10
ZA201405503B (en) 2015-12-23
AU2011384478A1 (en) 2014-08-14
EP2799431A1 (en) 2014-11-05
NO2799431T3 (pl) 2018-06-23
TWI546287B (zh) 2016-08-21
MX362940B (es) 2019-02-27
CN104024226A (zh) 2014-09-03
IL233385B (en) 2019-01-31
CA2861202A1 (en) 2013-07-04
BR112014016328A8 (pt) 2017-07-04
RU2014131011A (ru) 2016-02-20

Similar Documents

Publication Publication Date Title
ZA201405503B (en) Novel nicotinamide derivative or salt thereof
HRP20180646T1 (hr) Dispiropirolidinski derivat
TWI561512B (en) Novel nicotinamide derivative or salt thereof
HK1199840A1 (en) Noribogaine salt ansolvates
HK1188451A1 (zh) 咪唑並噁嗪化合物或其鹽
IL227664A0 (en) New heterocyclic histories
EP2915804A4 (en) NOVEL AMINE DERIVATIVE OR SALT OF IT
HK1199730A1 (zh) 哌啶化合物或其鹽
IL229064A0 (en) A new derivative of 3-hydroxyisothiazole 1-oxide
EP2727920A4 (en) DERIVED FROM 1,5-NAPHTHYRIDINE OR SALT THEREOF
EP2687531A4 (en) TETRAHYDROCARBOLINE DERIVATIVE
EP2740730A4 (en) DIBENZOOXEPINE DERIVATIVE
IL233001A0 (en) New iso-ergoline histories
GB201119594D0 (en) Novel heteroaromatic derivatives II
GB201119592D0 (en) Novel heteroaromatic Derivatives I